Immunohistochemical KIT (CD117) expression in thymic epithelial tumors

Chest

Volumn 128, Issue 1, 2005, Pages 140-144

  Nakagawa, Kazuo ^a   Matsuno, Yoshihiro ^a   Kunitoh, Hideo ^a   Maeshima, Arafumi ^a   Asamura, Hisao ^a   Tsuchiya, Ryosuke ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

c kit; KIT; Thymic carcinoma; Thymic epithelial tumor; Thymoma

Indexed keywords

CD5 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ARTICLE; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MEDIASTINUM TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; THYMIC EPITHELIAL TUMOR; THYMOMA; THYMUS CANCER; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

EID: 22244444500     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.1.140     Document Type: Article

References (28)

1. Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, Sobin LH, eds. Atlas of tumor pathology. 3rd series, fascicle 21. Washington, DC: The Armed Forces Institute of Pathology, 1997; 40-120
2. Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991; 15:67:1025-1032
3. Hsu CP, Chen CY, Chen CL, et al. Thymic carcinoma: ten years' experience in twenty patients. J Thorac Cardiovasc Surg 1994; 107:615-620
4. Lucchi M, Mussi A, Basolo F, et al. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg 2001; 19:566-569
5. Berezowski K, Grimes MM, Gal A, et al. CD5 immunoreactivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Am J Clin Pathol 1996; 106:483-486
6. Hishima T, Fukayama M, Fujisawa M, et al. CD5 expression in thymic carcinoma. Am J Pathol 1994; 145:268-275
7. Dorfman DM, Shahsafaei A, Chan JK. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity. Am J Surg Pathol 1997; 21:936-940
8. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6:3341-3351
9. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52:6139-6143
10. Turner AM, Zsebo KM, Martin F, et al. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80:374-381
11. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424:135-141
12. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993; 142:339-346
13. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11:728-734
14. Cole SR, Aylett GW, Harvey NL, et al. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. Leukemia 1996; 10:288-296
15. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998; 29:498-504
16. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-1703
17. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004; 130:222-224
18. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004; 202:375-381
19. Rosai J. Histological typing of tumors of the thymus: World Health Organization, international histological classification of tumors. 2nd ed. New York: Springer-Verlag, 1999
20. Caceres-Cortes JR, Alvarado-Moreno JA, Waga K, et al. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res 2001; 61:6281-6289
21. Kondoh G, Hayasaka N, Li Q, et al. An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis. Oncogene 1995; 10:341-347
22. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991; 51:2416-2419
23. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993; 53:1709-1714
24. Cohen PS, Chan JP, Lipkunskaya M, et al. Expression of stem cell factor and c-kit in human neuroblastoma: the Children's Cancer Group. Blood 1994; 84:3465-3472
25. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580
26. Tian Q, Frierson HF Jr, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999; 154:1643-1647
27. Piao X, Bernstein A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996; 87:3117-3123
28. Butnor KJ, Burchette JL, Sporn TA, et al. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004; 128:538-543